There are a spate of articles appearing the past couple weeks in biotech/pharma publications and the blogosphere with regard to struggles Big Pharma R&D groups are facing and what exactly to do about it. It can be generally stated that there is agreement within the industry and by industry observers that the current model is broken.
It takes too long. Costs too much. And fails to deliver too often - often spectacularly in phase III trials so as to maximize the loss of time and money. Big Pharma CEO's have commented on individual company plans at recent pharma meetings - variously calling for some level of retrenchment, cost cutting, out-sourcing to CROs, partnerships with academia and the public sector, narrowing the focus to niche areas or pursuing orphan drugs, or even diversifying into other businesses altogether like OTC or animal health.
I'm going publish a selection of these recent article and/or reblog several posts from leading commentators on the industry. Somewhere in there, the right models might be identified - at least for some companies. Happy hunting.
Posted by Bruce Lehr Feb 15th 2011.
Comments